EGFR and non-small cell lung carcinoma: In EGFR-TKI-resistant NSCLC cells, an RNA interference-mediated ADAM17 knockdown recovers the sensitivity to the EGFR-TKI gefitinib through the dephosphorylation of EGFR [128].